A recent phase III trial demonstrated that initial therapy with an immuno-agent improves PFS in patients with HR+, HER2- breast cancer. READ MORE
Genomic analysis revealed differences in the landscape of estrogen receptor-positive cancers when compared with ER+ primary tumors.
Observation for adverse reactions following trastuzumab serves as an unnecessary use of health resources.
Common menopausal symptoms can be used as predictive tools for adherence to the aromatase inhibitor tamoxifen.
Researchers conducted a study to generate estimates of costs associated with breast cancer adjuvant chemotherapy regimens.
A recent phase III trial demonstrated that initial therapy with an immuno-agent improves PFS in patients with HR+, HER2- breast cancer.
A recent study found that 29% of breast cancer clinical trials are not comprised of control arms consistent with the current standard of care.
A recent survey found that 90% of patients treated with radiation therapy for breast cancer found their experiences to be less “scary” than anticipated.
Breast cancer surgeons play a big role in deciding whether women with early-stage breast cancer undergo a controversial operation to have both breasts removed, even when cancer is found in only one.
Research in Review
An immuno-agent improves PFS and lowers the risk of death for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation.
A low level of stromal cytotoxic T-cell infiltration in breast cancer tumor specimens predicts patients who may benefit most from antibody- vs molecular-based HER2 inhibitors.
Researchers identified three quality measures that have the largest potential of improving quality of care at a system level for patients with early-stage breast cancer receiving systemic therapy.
A neoadjuvant chemotherapy combination used to treat breast cancer increases the risk of disease metastasis.
The American College of Obstetricians and Gynecologists has recently updated its clinical guidelines for the management of hereditary breast and ovarian cancer syndrome.